DaVita

DVA · NYSE

$175.35−$11.65 (−6.23%)TodayMarket closed · Oct 20, 7:48 PM ET

Prev close $187.00

DVA analyst rating

BuyConsensus of 5 analysts over the last 12 months. 60% rate it a buy.

Strong buy0
Buy3
Hold2
Underperform0
Sell0

12-month price target · 9 analysts

Average $224.74 (+28.2% upside)

Low: $169.98
Now: $175.35
High: $283.50

Upgrades and downgrades

The latest rating actions, newest first

DVA analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
TD Cowen	Aug 7, 2026	Upgrade	Hold → Buy	$201.00 → $220.00	67%
Truist Securities	Aug 7, 2026	Maintains	Hold	$250.00 → $215.00	67%
Barclays	Aug 5, 2026	Maintains	Equal-Weight	$218.00 → $224.00	59%
Truist Securities	Jul 14, 2026	Maintains	Hold	$205.00 → $250.00	67%
UBS	Jul 10, 2026	Maintains	Buy	$235.00 → $270.00	64%
Barclays	Jul 9, 2026	Maintains	Equal-Weight	$194.00 → $218.00	59%
TD Cowen	May 11, 2026	Maintains	Hold	$144.00 → $201.00	67%
Truist Securities	May 8, 2026	Maintains	Hold	$158.00 → $205.00	67%
Barclays	May 8, 2026	Maintains	Equal-Weight	$158.00 → $194.00	59%
UBS	May 7, 2026	Maintains	Buy	$190.00 → $235.00	64%

The case for and against

Updated Nov 7, 2025

Bull case

DaVita, as the largest provider of dialysis services in the United States with a 35% market share in clinics and over 3,000 facilities globally, serves approximately 280,000 patients each year. The company's revenue structure is heavily influenced by government payers, with about two-thirds of U.S. sales coming from Medicare reimbursement rates, while profits are predominantly driven by the 10% of patients covered by commercial insurers. Additionally, the backing of Berkshire Hathaway, which owns approximately 45% of DaVita, underscores a robust financial position despite mixed near-term fundamentals related to organic volume trends.

Bear case

DaVita faces significant risks that could adversely affect its financial performance, primarily stemming from reimbursement pressures that are heavily influenced by government payers, specifically Medicare, which accounts for about two-thirds of US sales. The company is also experiencing slowing organic trends and an unfavorable payer mix, particularly as commercial insurers contribute disproportionately to profits despite representing only 10% of patients treated. These factors create a challenging environment that may hinder DaVita's ability to sustain its profit margins and overall financial health.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.